EMAS Education

The 2020 edition of EMAS Care Online: The essential guide to women’s health in midlife and beyond is now available to EMAS members. Produced by EMAS,  the book provides  a practical, unbiased and non-promotional international guide for all professionals dealing with menopausal and postmenopausal women. It is accompanied by slide sets to aid teaching and…

Management of depressive symptoms in peri- and post-menopausal women: EMAS Clinical Guide

Amsterdam, 7 November, 2019 – A new position statement by the European Menopause and Andropause Society (EMAS) published in the journal Maturitas summarises the evidence about management of depression at the menopause. Globally, the total number of people with depression exceeds 300 million with a 70% greater incidence in women. The perimenopause is considered to…

EMAS travel award

EMAS travel award EMAS will support the travel costs for junior members who wish to attend international meetings and congresses; or, for example, those who wish to visit laboratories for specific short-term activities, such as collaborative research, or in order to learn new techniques. This is subject to them meeting the assessment criteria for these…

#EMAS2019 in the news

#EMAS2019 in the news Integrating novel scientific insights into clinical application the multidisciplinary international congress was extremely successful and enjoyed by all participants. As part of its menopause week, the BBC filmed speakers on both women’s and men’s health. The clips are below. We look forward to May 2021 when the next congress will be in…

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Collaborative Group on Hormonal Factors in Breast Cancer

30 August 2019 A meta-analysis covering the period January 1992 to January 2018 has been published in the Lancet by the Collaborative Group on Hormonal Factors in Breast Cancer. It has reported on the risk of breast cancer with MHT in relation to the type and timing of therapy. During prospective follow-up, 108 647 postmenopausal women…